Abstract

Adaptation of the functional proteome is essential to counter pathogens during infection, yet precisely timed degradation of these response proteins after pathogen clearance is likewise key to preventing autoimmunity. Interferon Regulatory Factor 1 (IRF1) plays an essential role as a transcription factor in driving the expression of immune response genes during infection. The striking difference in functional output with other IRFs, is that IRF1 also drives the expression of various cell cycle inhibiting factors, making it an important tumor suppressor. Thus, it is critical to regulate the abundance of IRF1 to achieve a 'Goldilocks' zone in which there is sufficient IRF1 to prevent tumorigenesis, yet not too much which could drive excessive immune activation. Using genetic screening, we identified the E3 ligase receptor Speckle Type BTB/POZ Protein (SPOP) to mediate IRF1 proteasomal turnover in human and mouse cells. We identified S/T-rich degrons in IRF1 required for its SPOP MATH domain-dependent turnover. In the absence of SPOP, elevated IRF1 protein levels functionally increased IRF1-dependent cellular responses, underpinning the biological significance of SPOP in curtailing IRF1 protein abundance.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Irene Schwartz

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  2. Milica Vunjak

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  3. Valentina Budroni

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6606-2031
  4. Adriana Cantoran García

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  5. Marialaura Mastrovito

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  6. Adrian Soderholm

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  7. Matthias Hinterndorfer

    Vienna BioCenter PhD Program, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2435-4690
  8. Melanie de Almeida

    Vienna BioCenter PhD Program, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  9. Kathrin Hacker

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  10. Jingkui Wang

    Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
  11. Kimon Froussios

    Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2812-0525
  12. Julian Jude

    Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9091-9867
  13. Thomas Decker

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9683-0620
  14. Johannes Zuber

    Research Institute of Molecular Pathology, Vienna Biocenter, Vienna, Austria
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8810-6835
  15. Gijs A Versteeg

    Department of Microbiology, Immunobiology and Genetics, University of Vienna, Vienna, Austria
    For correspondence
    gijs.versteeg@univie.ac.at
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6150-2165

Funding

Stand-Alone grant (P30231-B)

  • Gijs A Versteeg

Stand-Alone grant (P30415-B)

  • Gijs A Versteeg

Special Research grant (SFB grant F79)

  • Gijs A Versteeg

Doctoral School grant from the Austrian Science Fund (DK grant W1261)

  • Thomas Decker
  • Gijs A Versteeg

European Research Council (ERC-StG-336860)

  • Johannes Zuber

Austrian Science Fund (SFB grant F4710)

  • Johannes Zuber

Stand-Alone grant (P25186-B22)

  • Thomas Decker

Special Research Grant (SFB grant F6103)

  • Thomas Decker

DOC fellowship of the Austrian Academy of Sciences

  • Milica Vunjak
  • Valentina Budroni
  • Melanie de Almeida
  • Thomas Decker

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2023, Schwartz et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 958
    views
  • 133
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Irene Schwartz
  2. Milica Vunjak
  3. Valentina Budroni
  4. Adriana Cantoran García
  5. Marialaura Mastrovito
  6. Adrian Soderholm
  7. Matthias Hinterndorfer
  8. Melanie de Almeida
  9. Kathrin Hacker
  10. Jingkui Wang
  11. Kimon Froussios
  12. Julian Jude
  13. Thomas Decker
  14. Johannes Zuber
  15. Gijs A Versteeg
(2023)
SPOP targets the immune transcription factor IRF1 for proteasomal degradation
eLife 12:e89951.
https://doi.org/10.7554/eLife.89951

Share this article

https://doi.org/10.7554/eLife.89951

Further reading

    1. Immunology and Inflammation
    Josep Garnica, Patricia Sole ... Pere Santamaria
    Research Article

    Chronic antigenic stimulation can trigger the formation of interleukin 10 (IL-10)-producing T-regulatory type 1 (TR1) cells in vivo. We have recently shown that murine T-follicular helper (TFH) cells are precursors of TR1 cells and that the TFH-to-TR1 cell transdifferentiation process is characterized by the progressive loss and acquisition of opposing transcription factor gene expression programs that evolve through at least one transitional cell stage. Here, we use a broad range of bulk and single-cell transcriptional and epigenetic tools to investigate the epigenetic underpinnings of this process. At the single-cell level, the TFH-to-TR1 cell transition is accompanied by both, downregulation of TFH cell-specific gene expression due to loss of chromatin accessibility, and upregulation of TR1 cell-specific genes linked to chromatin regions that remain accessible throughout the transdifferentiation process, with minimal generation of new open chromatin regions. By interrogating the epigenetic status of accessible TR1 genes on purified TFH and conventional T-cells, we find that most of these genes, including Il10, are already poised for expression at the TFH cell stage. Whereas these genes are closed and hypermethylated in Tconv cells, they are accessible, hypomethylated, and enriched for H3K27ac-marked and hypomethylated active enhancers in TFH cells. These enhancers are enriched for binding sites for the TFH and TR1-associated transcription factors TOX-2, IRF4, and c-MAF. Together, these data suggest that the TR1 gene expression program is genetically imprinted at the TFH cell stage.

    1. Genetics and Genomics
    2. Immunology and Inflammation
    Stephanie Guillet, Tomi Lazarov ... Frédéric Geissmann
    Research Article

    Systemic lupus erythematosus (SLE) is an autoimmune disease, the pathophysiology and genetic basis of which are incompletely understood. Using a forward genetic screen in multiplex families with SLE, we identified an association between SLE and compound heterozygous deleterious variants in the non-receptor tyrosine kinases (NRTKs) ACK1 and BRK. Experimental blockade of ACK1 or BRK increased circulating autoantibodies in vivo in mice and exacerbated glomerular IgG deposits in an SLE mouse model. Mechanistically, NRTKs regulate activation, migration, and proliferation of immune cells. We found that the patients’ ACK1 and BRK variants impair efferocytosis, the MERTK-mediated anti-inflammatory response to apoptotic cells, in human induced pluripotent stem cell (hiPSC)-derived macrophages, which may contribute to SLE pathogenesis. Overall, our data suggest that ACK1 and BRK deficiencies are associated with human SLE and impair efferocytosis in macrophages.